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Summary
Introduction—Platelet activation via the Fcγ receptor IIa (FcγRIIa) is implicated in the 
pathogenesis of immune complex (IC)-mediated thrombocytopenia and thrombosis (ITT). We 
previously showed that ICs composed of antigen and antibodies targeting CD40 ligand (CD40L) 
or β2 Glycoprotein I (β2GPI) induce ITT in mice transgenic for human FcγRIIa (hFcR) but not 
wild-type controls (which lack FcγRIIa). Here we evaluated the contribution of the guanine 
nucleotide exchange factor, CalDAG-GEFI, and P2Y12, key regulators of Rap1 signaling in 
platelets, to ITT induced by these clinically relevant ICs.
Methods—Pre-formed anti-CD40L or anti-β2GPI ICs were injected into hFcR/Caldaggef1+/+ or 
hFcR/Caldaggef1-/- mice, with or without clopidogrel pre-treatment. Animals were observed for 
symptoms of shock for 30 minutes, during which time core body temperature was monitored. 
Platelet counts were obtained before and 30 minutes after IC injection. Lungs were assessed for 
thrombosis by histology or near-infrared imaging.
Results—Both CD40L and β2GPI ICs rapidly induced severe thrombocytopenia, shock and a 
reduction in body temperature in hFcR/Caldaggef1+/+ mice. hFcR/Caldaggef1-/- mice were 
protected from CD40L and β2GPI IC-induced thrombocytopenia and shock, whereas P2Y12 
inhibition had only a modest effect on IC-induced ITT. Consistent with these findings, IC-induced 
integrin activation in vitro and the accumulation of activated platelets in the lungs of IC-
challenged mice was strongly dependent on CalDAG-GEFI.
Conclusions—Our studies demonstrate that CalDAG-GEFI plays a critical role in platelet 
activation, thrombocytopenia and thrombosis induced by clinically relevant ICs in mice. Thus, 
CalDAG-GEFI may be a promising target for the intervention of IC-associated, FcγRIIa-mediated 
thrombotic conditions.
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Introduction
Platelets are essential components of the hemostatic response to vascular injury. However, 
platelets also play a role in pathologic atherothrombotic thrombosis and in immune-
mediated thrombocytopenia and thrombosis (ITT) syndromes, including heparin-induced 
thrombocytopenia and thrombosis (HIT) [1,2], thrombocytopenia and disseminated 
intravascular coagulation associated with bacterial sepsis [3], and antiphospholipid 
syndrome [4,5]. Thrombotic complications have also been observed with the use of 
therapeutic IgG antibodies, such as bevacizumab and anti-CD40 ligand (anti-CD40L) 
monoclonal antibodies [6,7]. Critical to antibody-induced activation is FcγRIIa, a receptor 
for IgG immune complexes [8].
Clustering of platelet FcγRIIa triggers a signaling response that is typical for 
immunoreceptor tyrosine-based activation motif (ITAM) receptors. Binding of the non-
receptor tyrosine kinase Syk initiates the formation of a signalosome, consisting of various 
adapter and effector proteins, which is critical for the activation of phospholipase Cγ2 
(PLCγ2), and thus the generation of the second messengers calcium (Ca2+) and 
diacylglycerol (DAG) [9]. The small GTPase Rap1 orchestrates platelet activation 
downstream of PLCγ2. Two independent yet synergistic signaling pathways control the 
activation state of Rap1. Rapid but reversible activation of Rap1 depends on the guanine 
nucleotide exchange factor, CalDAG-GEFI (RasGRP2), which responds to increases in 
cytosolic Ca2+. Sustained Rap1 activation, however, requires signaling by protein kinase C 
and the Gi-coupled receptor for ADP, P2Y12, the target of the anti-platelet drug clopidogrel 
bisulfate (Plavix). In our recent work, we showed that platelet activation by ITAM receptors 
is strongly dependent on CalDAG-GEFI [10,11]. However, the contribution of Rap1 
signaling to ITT induced by clinically relevant ICs has not been determined.
We recently established novel mouse models for ITT induced by CD40L/anti-CD40L and 
β2-GPI/anti β2-GPI ICs [12,13]. Both anti-CD40L (monoclonal) and anti-β2-GPI 
(polyclonal) antibodies form multivalent ICs when combined with their respective antigens. 
CD40L antibody was chosen for its capacity to bind a therapeutically relevant antigen, 
whereas β2-GPI antibody was selected for the importance of this antigen in autoimmunity. 
In these models of acute ITT, ICs injected intravenously into mice transgenic for FcγRIIA 
[14] cause rapid onset shock, a fall in platelet count, and deposition of fibrin rich thrombi in 
the lungs [15,12,13]. In an effort to identify an effective therapeutic strategy against ITT in 
this model, we tested anticoagulant and anti-platelet drugs by means of pretreatment prior to 
IC challenge. Bivalirudin, heparin, and aspirin, however, were largely ineffective in this 
regard (unpublished data). In search of a more effective target, we here assessed the role of 
CalDAG-GEFI and P2Y12, critical regulators of Rap1 signaling in platelets, in ITT.
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Hybridoma cells were obtained from American Type Culture Collection (Manassas, VA). 
M90 (monoclonal anti-human CD40L IgG1 mAb, ATCC HB-12055) was purified into 
azide-free PBS from conditioned media by protein-G chromatography. Polyclonal goat anti-
human β2GPI antibody (which does not bind mouse β2GPI) was from Affinity Biologicals 
(Ancaster, ON, Canada). Anti-human-FcγRIIa mAb, IV.3, was from StemCell Technologies 
(Vancouver, BC, Canada). The phycoerythrin (PE)-labeled anti-mouse αIIbβ3 mAb, JON/A-
PE, was from Emfret Analytics (Eibelstadt, Germany). Antibodies against mouse P-selectin 
were obtained from BD Biosciences and labeled with Alexa-800 (Invitrogen, Grand Island, 
NY). Purified human β2GPI was from Haemotologic Technologies (Essex Junction, VT). 
Recombinant soluble human CD40L was from PeproTech (Rocky Hill, NJ). Clopidogrel 
(Plavix) was from Sanofi-Aventis (Bridgewater NJ). 2-methylthio-adenosine 5′-
monophosphate triethylammonium salt hydrate (2-MeSAMP, P2Y12 inhibitor) was from 
Biolog (Farmingdale, NY). Preformed ICs were prepared in a microfuge tube by mixing the 
antibody (anti-CD40L or anti- β2GPI) with antigen (CD40L or β2GPI) in PBS at balanced 
stoichiometry and incubated 5 minutes at room temperature prior to use.
Mice
Mice transgenic for human FcγRIIa (FCGR2A, or “hFcR”) [14] and Caldaggef1-deficient 
mice [16], as well as littermate wild type (WT) controls, were bred on a C57BL6/J strain 
background. hFcR and Caldaggef1-deficient mice were crossed to create hFcR/
Caldaggef1-/- (hFcR/CDGI /-) mice. FcγRIIa and Caldaggef1 genotypes were verified by 
PCR analysis. All experimental procedures were approved by the Animal Care and Use 
Committee of the University of North Carolina. Where indicated, mice were treated (by oral 
gavage) with clopidogrel (75 mg/kg) 24 and 3 hours before the experiment.
Flow cytometry
Platelet surface FcγRIIa expression was measured in blood (50 μl) drawn from the retro-
orbital plexus of anesthetized mice into heparin-coated capillary tubes (VWR, Arlington 
Heights IL). Samples were stained with a PE-labeled antibody against GPIbα and an 
Alexa488-labeled antibody against FcγRIIa (IV.3). FcγRIIa surface expression was 
determined as the mean Alexa 488 fluorescence intensity for all GPIbα posivite events. For 
counting platelets, blood samples were stained with anti-GPIbα-PE, and platelets were 
counted by flow cytometry gating for PE-positive events. Platelet counts at t = 0 were 
defined as 100%. For measurement of ADP or IC-induced platelet activation ex vivo, diluted 
blood samples were activated with ADP (10 μM) or IC (500nM) in the presence of JON/A-
PE for 10 minutes and analyzed immediately.
Rap1 activation assay
To assess IC-induced Rap1 activation in platelets from hFcR/CDGI+/+ and hFcR/CDGI-/- 
mice, washed platelets (2.5 × 108/ml; 250 μl vol) were stimulated with anti-CD40L or anti-
β2GPI IC in standard aggregometry for 3 minutes in the presence or absense of the P2Y12 
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inhibitor 2-MeSAMP (100 μM). Reactions were stopped and platelets were lysed with ice-
cold 2× lysis buffer (100mM Tris/HCl, pH 7.4, 400mM NaCl, 5mM MgCl2, 2% Nonidet 
P-40, 20% glycerol, and complete protease inhibitor cocktail lacking 
ethylenediaminetetraacetic acid; 15 minutes). Rap1-GTP was precipitated from platelet 
lysates using RalGDS-RBD beads as described previously [16]. Pellets were solubilized in 
sample buffer (75mM Tris/HCl pH 6.8, 10% SDS, 10% glycerol, 5% 2-mercaptoethanol, 
0.004% bromophenol blue), proteins separated by SDS-PAGE, and Rap1 detected by 
Western blotting. Small aliquots were saved to control that each sample contained equal 
amounts of proteins.
Assessment of immune complex-induced thrombotic thrombocytopenia
Fifteen minutes prior to IC injection, mice were anesthetized with isoflurane and Alexa800-
coupled antibodies to P-selectin (1 μg/g body weight) were administered by retro-orbital 
injection for in vivo labeling of activated platelets. Preformed ICs were prepared by mixing 
120 μg Ab (anti-CD40L or anti-β2-GPI in PBS) with corresponding Ag (hCD40L [8 μg] or 
hβ2-GPI [20 μg] in PBS) respectively. Solutions (200 μl) were incubated for 5 minutes at RT 
prior to injection. Central body temperature of each animal was recorded immediately prior 
to IC injection. Animals received tail vein IC injections (200 μl) and were observed 
continuously for 30 minutes. Apparent symptoms of thrombotic shock for each animal were 
assessed based on observations of balance, mobility and respiration, and recorded as severe 
(complete immobility, loss of consciousness), moderate (impaired mobility, irregular 
respiration), mild (lethargy, shallow respiration), or none.
In addition, post IC body temperatures were measured every 10 minutes. At 30 minutes 
blood was drawn retro-orbitally and platelets were counted as described above. The lungs 
were carefully flushed with 1 ml PBS by left ventricular cardiac puncture, removed en bloc, 
and incubated in 4% paraformaldehyde for 24 hours before analysis on a LI-COR Odyssey 
scanner (LI-COR Biosciences, Lincoln NE). The lungs were also processed by H&E 
staining of 5 μm paraffin sections for the visualization of intravascular thrombi.
Statistical analysis
Results are reported as mean ± standard deviation. Differences between groups were 
analyzed by two-way Analysis of Variance (ANOVA). P values of < 0.05 were considered 
statistically significant.
Results and discussion
In order to evaluate the role of CalDAG-GEFI in IC-induced FcγRIIa-mediated 
thrombocytopenia and thrombosis, mice transgenic for human FcγRIIa either having or 
lacking Caldaggef1 (hFcR/CDGI+/+ or hFcR/CDGI-/-, respectively) were challenged with 
anti-CD40L+hCD40L or anti-β2GPI+hβ2GPI immune complexes. To evaluate the 
contribution of P2Y12 activation pathway, select groups of hFcR/CDGI+/+ or hFcR/CDGI-/- 
mice were given clopidogrel before IC injection. The expression level of hFcγRIIa was 
similar between hFcR/CDGI+/+ and hFcR/CDGI-/- mice (not shown). P2Y12 function as 
assessed by measuring ADP-induced αIIbβ3 activation ex vivo, was abolished in 
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clopidogrel-treated mice (not shown). Consistent with previous work [16], ADP-induced 
integrin activation was also abolished in platelets lacking CalDAG-GEFI (hFcR/CDGI-/-).
Intravenous injection of anti-CD40L or anti-β2GPI immune complexes in hFcR/CDGI+/+ 
mice rapidly induced moderate to severe symptoms of thrombotic shock as evidenced by 
disorientation, shallow irregular breathing, and impaired mobility (Fig 1A,B). Shock 
symptoms correlated with a significant drop in central body temperature (Fig 1C,D). We 
previously showed that injection of either antibody or antigen alone does not cause any 
symptoms in hFcR/CDGI+/+ mice. Also, we have determined that platelets are the primary 
mediators of IC-induced thrombotic shock in this model since both ICs failed to cause 
thrombotic shock and hypothermia in thrombocytopenic hFcR mice [13].
hFcR/CDGI-/- mice were largely protected from shock and hypothermia induced by anti-
CD40L ICs (Fig 1A,C), whereas the protection was partial when challenged with anti-β2GPI 
ICs (Fig 1B,D). In contrast, clopidogrel treatment provided little to no protection from ITT-
induced shock and hypothermia, both in hFcR/CDGI+/+ and hFcR/CDGI-/- mice.
Immune complex injection also induced profound thrombocytopenia in hFcR/CDGI+/+ mice 
(Figure 1E,F). Consistent with the hypothesis that FcγRIIa-mediated platelet activation is 
critical to ITT, peripheral platelet counts were significantly higher in hFcR/CDGI-/- mice 
challenged with anti-CD40L and anti-β2GPI ICs (Figure 1E,F). In contrast, IC-induced 
thrombocytopenia was only minimally affected by pre-treatment with clopidogrel.
To confirm that hFcR/CDGI-/- mice are protected from ITT due to impaired platelet 
activation and thrombosis, we evaluated IC-induced platelet activation in vitro and in vivo. 
We first added anti-CD40L or anti-β2GPI ICs to platelets obtained from hFcR/CDGI+/+ and 
hFcR/CDGI-/- mice in the presence or absence of the P2Y12 inhibitor 2-MeSAMP. Both ICs 
strongly activated hFcR/CDGI+/+ platelets, as evidenced by Jon/A-PE binding (Fig 2A,B). 
IC-induced platelet activation was significantly inhibited by CalDAG-GEFI deficiency and, 
to a much lesser extent, by P2Y12 inhibition. The combination of CalDAG-GEFI deficiency 
and P2Y12 inhibition resulted in a further reduction in IC-induced platelet activation. 
Consistently, IC-induced aggregation (Fig. 2C,D) and Rap1 activation (Fig. 2E) were 
markedly reduced in hFcR/CDGI-/- platelets, and to a lesser degree in 2-MeSAMP-treated 
hFcR/CDGI+/+ platelets. Taken together, these results demonstrate a correlation between 
reduced Rap1 activation and IC-induced platelet activation.
To quantify and visualize platelet activation in vivo, we used near-infrared imaging to 
monitor the accumulation of P-selectin-positive, activated platelets in the lungs of animals 
(Fig. 3A,B). Injection of anti-CD40L or anti-β2GPI ICs caused a marked accumulation of 
activated platelets in the lungs of hFcR/CDGI+/+ mice, consistent with the pervasive 
intravascular thrombi observed in H&E tissue sections (Fig 3C,D). In mice challenged with 
anti-CD40L IC, CalDAG-GEFI deficiency virtually abolished pulmonary thrombosis, 
whereas clopidogrel treatment was only partially effective (Fig 3E,F). CalDAG-GEFI 
deficiency but not clopidogrel treatment conferred partial protection from β2GPI IC-induced 
thrombosis. It is unclear why CalDAG-GEFI deficiency had a greater impact in vivo with 
CD40L ICs than with β2GPI ICs. It is possible that the differences in activity between the 
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two ICs could be a consequence of the more heterogeneous nature of polyclonal β2GPI IC 
structures (CD40L antibody is monoclonal). For example, we have observed with HPLC 
SEC that β2GPI antibodies appear to create a significantly wider range of IC sizes (0.5 to <2 
mega Daltons) than CD40L mAb (<1 mega Dalton; not shown).
Our results showing impaired FcγRIIa-dependent activation of platelets isolated from mice 
treated with clopidogrel are in agreement with previous in vitro work suggesting that 
commonly used P2Y12 inhibitors may prevent ITT/HIT [17]. This defect in activation, 
however, only led to a mild protection from IC-induced ITT in vivo, a finding that is in line 
with clinical observations [18].
In contrast, deficiency in CalDAG-GEFI, a critical mediator of P2Y12-independent 
activation of Rap1 and integrin αIIbβ3 in platelets, provided significant protection with both 
ICs tested. These findings are consistent with our previous studies, where we identified a 
critical role for CalDAG-GEFI in ITAM-dependent platelet activation, both in vitro and in 
vivo [10,19,11]. ITAM-coupled receptors rely on the ability of the CalDAG-GEFI/Rap1 
signaling module to respond to small increases in the cytosolic Ca2+ concentration, 
facilitating granule release and engagement of the P2Y12 signaling pathway [20]. 
Importantly, however, CalDAG-GEFI is less critical for thrombin-dependent platelet 
activation, and the hemostatic response in Caldaggef1-/- mice was significantly better when 
compared to WT mice treated clopidogrel [21]. Thus, targeting CalDAG-GEFI may be a 
viable strategy to safely prevent thrombotic complications in ITT.
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CalDAG-GEFI deficiency protects mice from IC-induced thrombocytopenia and thrombotic 
shock. Symptoms of thrombotic shock following the intravenous injection of anti-CD40L 
(A) or anti-β2GPI (B) immune complexes in hFcR/CDGI+/+ but not hFcR/CDGI-/- mice. 
Central body temperature of mice was measured before and at 10, 20, and 30 minutes after 
the injection of anti-CD40L (C) or antiβ2GPI (D) in hFcR/CDGI+/+ (open circles; [n=8] for 
anti-CD40L IC; [n=4] for anti-β2GPI IC), hFcR/CDGI-/- (open triangles; n=8 for anti-
CD40L IC; n=5 for anti-β2GPI IC), hFcR/CDGI+/+ mice with clopidogrel (closed circles; 
[n=8] for anti-CD40L IC; [n=4] for anti-β2GPI IC), and hFcR/CDGI-/- mice with 
clopidogrel (closed triangles; [n=7] for anti-CD40L IC; [n=4] for anti-β2GPI IC). (*) 
indicates statistically significant difference. Platelet counts were determined by flow 
cytometry before and thirty minutes after the injection of anti-CD40L (E) or antiβ2GPI (F) 
ICs. Post injection values are presented as percent of pre-injection values.
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CalDAG-GEFI deficiency inhibits IC-induced platelet activation and aggregation as well as 
IC-induced Rap1 activation (A-B). Flow cytometric analysis of platelet αIIbβ3 activation 
(Jon/A-PE; [22]) induced by anti-CD40L (A) or anti-β2GPI (B) ICs (C-D). Aggregation of 
washed platelets in reponse to anti-CD40L (C), or anti-β2GPI (D) ICs. Arrows point to the 
time point when the indicated concentration of IC was added to the reaction mixture. (E) 
Determination of Rap1-GTP levels in lysates from platelets aggregated with anti-CD40L or 
anti-β2GPI ICs. Total Rap1 levels in platelet lysates are shown as loading controls.
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Quantitative analysis of activated platelet accumulation in the lungs of mice following the 
injection of anti-CD40L (A) or anti-β2GPI (B) ICs; (*) indicates statistically significant 
difference compared to the hFcR/CD+/+ group. Representative near-infrared images of lungs 
harvested from respective mice are shown. Intravascular microthrombi were analyzed by 
H&E staining histology. Representative sections of lungs harvested from hFcR/CDGI+/+ and 
hFcR/CDGI-/- mice injected with anti-CD40L ICs (C-F) are shown.
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